Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer
Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK
The first-in-class, oral, potent, and selective small-molecule competitive inhibitor of anaplastic lymphoma kinase (ALK), crizotinib, was found to have a durable overall response rate and a median progression-free survival of 8.1 months in patients with ALK-positive non–small-cell lung cancer (NSCLC), according to results of a global phase 2 study presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.INTENDED AUDIENCE:
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with Lung Cancer.Activity Objectives:
After participating in this educational activity, participants should be better able to:
- Identify patients with non–small-cell lung cancer (NSCLC) who may benefit from targeted treatment with an anaplastic lymphoma kinase (ALK) inhibitor.
- Evaluate the safety and efficacy of ALK inhibitor for the management of advanced NSCLC.
Click Next to begin reading the activity.